Cargando…

A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2

Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it....

Descripción completa

Detalles Bibliográficos
Autores principales: Kivrak, Arif, Ulaş, Berdan, Kivrak, Hilal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703546/
https://www.ncbi.nlm.nih.gov/pubmed/33290969
http://dx.doi.org/10.1016/j.intimp.2020.107232
_version_ 1783616660312162304
author Kivrak, Arif
Ulaş, Berdan
Kivrak, Hilal
author_facet Kivrak, Arif
Ulaş, Berdan
Kivrak, Hilal
author_sort Kivrak, Arif
collection PubMed
description Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it. Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients. They prevent cytokine storm that is the main reason of deaths related to SARS-CoV-2. In addition, anti-inflammatory agents have critical roles to inhibit the lung injury and multisystem organ dysfunction. The combination with anti-viral drugs with other drugs displays high synergistic effects. In the present study, the drugs used for Covid-19 are analyzed and compare the efficiency for the Covid-19 patients from the different continents including USA, South Korea, Italy, Spain, Germany, Russia, Brazil, Turkey, and China. Nowadays, all countries tried to find vaccine and new drug candidates for SARS-CoV-2, but anti-viral drugs may be the best candidates for the treatment of Covid-19 before finding novel anti-Covid drug.
format Online
Article
Text
id pubmed-7703546
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-77035462020-12-01 A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2 Kivrak, Arif Ulaş, Berdan Kivrak, Hilal Int Immunopharmacol Review Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it. Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients. They prevent cytokine storm that is the main reason of deaths related to SARS-CoV-2. In addition, anti-inflammatory agents have critical roles to inhibit the lung injury and multisystem organ dysfunction. The combination with anti-viral drugs with other drugs displays high synergistic effects. In the present study, the drugs used for Covid-19 are analyzed and compare the efficiency for the Covid-19 patients from the different continents including USA, South Korea, Italy, Spain, Germany, Russia, Brazil, Turkey, and China. Nowadays, all countries tried to find vaccine and new drug candidates for SARS-CoV-2, but anti-viral drugs may be the best candidates for the treatment of Covid-19 before finding novel anti-Covid drug. Elsevier B.V. 2021-01 2020-11-30 /pmc/articles/PMC7703546/ /pubmed/33290969 http://dx.doi.org/10.1016/j.intimp.2020.107232 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Kivrak, Arif
Ulaş, Berdan
Kivrak, Hilal
A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2
title A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2
title_full A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2
title_fullStr A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2
title_full_unstemmed A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2
title_short A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2
title_sort comparative analysis for anti-viral drugs: their efficiency against sars-cov-2
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703546/
https://www.ncbi.nlm.nih.gov/pubmed/33290969
http://dx.doi.org/10.1016/j.intimp.2020.107232
work_keys_str_mv AT kivrakarif acomparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2
AT ulasberdan acomparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2
AT kivrakhilal acomparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2
AT kivrakarif comparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2
AT ulasberdan comparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2
AT kivrakhilal comparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2